EUCTR2007-005886-36-GB进行中（未招募）不适用
A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of AVE0010 in patients with Type 2 diabetes insufficiently controlled with basal insulin. - GETGOAL
Sanofi -Aventis Recherche & Développement0 个研究点目标入组 450 人开始时间: 2010年12月17日最近更新:
适应症
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 450
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients meeting all of the following inclusion criteria will be screened: • Patients with type 2 diabetes mellitus, as defined by Fasting plasma glucose = 7 mmol/L (126 mg/dL) or 2 hours postprandial plasma glucose = 11.1 mmol/L (200 mg/dL) and diagnosed for at least 1 year at the time of the screening visit, insufficiently controlled with basal insulin, i.e. the clinical need of treatment intensification with a short-acting insulin or the inability to increase the baseline basal insulin dose due to hypoglycemia. • Written informed consent obtained.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Patients presenting with any of the following criteria will not be included in the study: • Exclusion criteria related to study methodology - HbA1c <7.0 % or HbA1c >10 % at screening. - At the time of screening age 250 mg/dL (>13.9 mmol/l). - History of hypoglycemia unawareness. - Body Mass Index (BMI) =20 kg/m². - Weight change of more than 5 kg during the 3 months preceding the screening visit. - History of unexplained pancreatitis, chronic pancreatitis, pancreatectomy, stomach/gastric surgery, inflammatory bowel disease. - History of metabolic acidosis, including diabetic ketoacidosis within 1 year prior to screening. - Hemoglobinopathy or hemolytic anemia, receipt of blood or plasma products within 3 months prior to the time of screening. - Within the last 6 months prior to screening: History of myocardial infarction, stroke, or heart failure requiring hospitalization. - Known history of drug or alcohol abuse within 6 months prior to the time of screening. - Cardiovascular, hepatic, neurological, endocrine disease, active malignant tumor or other major systemic disease or patients with short life expectancy making implementation of the protocol or interpretation of the study results difficult, history or presence of clinically significant diabetic retinopathy, history or presence of macular edema likely to require laser treatment within the study period. - Uncontrolled or inadequately controlled hypertension at the time of screening with a resting systolic or diastolic blood pressure >180 mmHg or >95 mmHg, respectively. - Laboratory findings at the time of screening. - AST, ALT or ALP: >2 times the upper limit of the normal laboratory range, - Amylase and/or lipase: >3 times the upper limit of the normal laboratory range, - Total bilirubin: >1.5 times the upper limit of the normal laboratory range (except in case of Gilbert’s syndrome), - Hemoglobin <11 g/dL and/or neutrophils <1,500/mm3 and/or platelets <100,000/mm3, - Positive test for Hepatitis B surface antigen and/or Hepatitis C antibody, - Positive serum pregnancy test in females of childbearing potential. - Any clinically significant abnormality identified on physical examination, laboratory tests, ECG or vital signs at the time of screening that in the judgment of the investigator or any sub investigator would preclude safe completion of the study or constrains efficacy assessment. - Patients considered by the investigator or any sub investigator as inappropriate for this study for any reason. - Use of other oral or injectable antid
研究者
相似试验
进行中（未招募）
1 期
A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of AVE0010 in patients with Type 2 diabetes insufficiently controlled with basal insulin. - GETGOALType II DiabetesMedDRA version: 10.1Level: LLTClassification code 10067585Term: <Manually entered code. Term in E.1.1>EUCTR2007-005886-36-DESanofi -Aventis Recherche & Développement450
进行中（未招募）
不适用
Efficacy and safety of lixisenatide versus placebo on top of basal insulin and/or oral antidiabetic treatment in older type 2 diabetic patientsType 2 Diabetes mellitusMedDRA version: 14.1Level: PTClassification code 10067585Term: Type 2 diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2012-003292-19-ESSanofi-Aventis Recherche & Développement340
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter 24-week study followed by an extension assessing the efficacy and safety of AVE0010 on top of a sulfonylurea in patients with type 2 diabetes not adequately controlled with sulfonylurea - GETGOAL-SEUCTR2007-005881-11-CZSanofi-Aventis Recherche&Développement855
进行中（未招募）
不适用
A randomized, double-blind, placebo-controlled, 2-arm parallel-group, multicenter study with a 24-week main treatment period and an extension assessing the efficacy and safety of AVE0010 on top of pioglitazone in patients with type 2 diabetes not adequately controlled with pioglitazone. - GETGOAL-PEUCTR2007-005884-92-GRSanofi-Aventis Recherche & Développement450
进行中（未招募）
1 期
Dupilumab in CRSsNPEUCTR2020-003117-35-HUSanofi-aventis Recherche & Développement437